衞光生物(002880.SZ):部分募投項目延期
格隆匯8月19日丨衞光生物(002880.SZ)公佈,公司於2021年8月19日分別召開第二屆董事會第四十次會議、第二屆監事會第二十九次會議,審議通過了《關於部分募集資金投資項目延期的議案》,同意根據公司目前募投項目的實施進度,在募投項目實施主體、募集資金用途及投資項目規模不發生變更的情況下,對部分募投項目進行延期,該事項在董事會審批範圍內,無需提交公司股東大會審議批准。

特異性免疫球蛋白及凝血因子類產品產業化項目及工程技術研究開發中心建設項目延期原因為受國家藥品審評審批制度改革的影響,研發過程中藥學及臨牀研究技術要求不斷提高,必須嚴格執行審評審批制度流程要求,因此凍幹人用狂犬病疫苗(雞胚細胞)、人凝血酶原複合物、人凝血因子VIII的研發及產業化進程均有不同程度的延期。
鐘山漿站新建項目延期原因為受原項目實施地點被政府徵地影響以及2020年初爆發新冠疫情,項目於2020年8月方正式施工。項目為購置土地並新建採漿業務用房,項目一期主體工程基本完成,現處於裝修招投標階段,二期建設正在規劃中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.